Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally advanced setting or with chemotherapy in first-line...

Full description

Bibliographic Details
Main Authors: Olivia Leblanc, Sophie Vacher, Charlotte Lecerf, Emmanuelle Jeannot, Jerzy Klijanienko, Frédérique Berger, Caroline Hoffmann, Valentin Calugaru, Nathalie Badois, Anne Chilles, Maria Lesnik, Samar Krhili, Ivan Bieche, Christophe Le Tourneau, Maud Kamal
Format: Article
Language:English
Published: China Anti-Cancer Association 2020-02-01
Series:Cancer Biology & Medicine
Subjects:
head and neck squamous cell carcinoma
cetuximab
biomarker
pik3ca
ras
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1550

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1550

Similar Items